Form 4: Apogee CFO Sells Shares Under 10b5-1 Plan

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 2,000 shares of common stock for $65 per share, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc. (APGE), reported a sale of common stock.
• The transaction involved the disposition of 2,000 shares of Apogee Therapeutics common stock.
• The shares were sold at a price of $65 per share.
• The transaction date was November 14, 2025.
• Following this transaction, Jane Henderson beneficially owns 197,871 shares of common stock directly.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned insider sale under a Rule 10b5-1 plan, which typically indicates a neutral sentiment as it is not based on new material non-public information. It's a routine disclosure rather than a signal of management's immediate view on the company's prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The sale of 2,000 shares by a key executive is a minor dilution event but is generally considered routine when executed under a 10b5-1 plan, minimizing concerns about management's confidence in the company.

Key Dates

Keywords

Apogee Therapeutics, APGE, Insider Transaction, Form 4, Jane Henderson, Chief Financial Officer, Stock Sale, 10b5-1 Plan, Equity Disclosure